Indeed, Craig Jordan’s lab showed that primitive CD34+/CD38−/CD123+ AML cells aberrantly express active NF-κB, and that in vitro cell treatment with proteasome inhibitors is sufficient to induce rapid cell death. The gene discussed is CD38; the disease is acute myeloid leukemia.